Dr. Mark Pegram, MD. Stanford Medicine.

Summus-affiliated physician discusses the latest in HER2-positive breast cancer

By Summus | August 28, 2017
Mark Pegram, MD, recently spoke with OncLive about developments and the future of HER2-positive breast cancer. Dr. Pegram, a member of the Summus physician network, is director of the Stanford Breast Oncology Program and associate director for clinical research at the Stanford Cancer Institute.

Read Dr. Pegram’s interview with OncLive here.
Share this post